These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15549307)

  • 1. Immunogenicity of human embryonic stem cells: can we achieve tolerance?
    Drukker M
    Springer Semin Immunopathol; 2004 Nov; 26(1-2):201-13. PubMed ID: 15549307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity of human embryonic stem-derived cells.
    Drukker M; Benvenisty N
    Trends Biotechnol; 2004 Mar; 22(3):136-41. PubMed ID: 15036864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
    Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
    Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.
    Tang C; Drukker M
    Semin Immunopathol; 2011 Nov; 33(6):563-72. PubMed ID: 21479877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro.
    Zhan X; Dravid G; Ye Z; Hammond H; Shamblott M; Gearhart J; Cheng L
    Lancet; 2004 Jul 10-16; 364(9429):163-71. PubMed ID: 15246729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression.
    Magliocca JF; Held IK; Odorico JS
    Stem Cells Dev; 2006 Oct; 15(5):707-17. PubMed ID: 17105406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance induction to human stem cell transplants with extension to their differentiated progeny.
    Lui KO; Howie D; Ng SW; Liu S; Chien KR; Waldmann H
    Nat Commun; 2014 Dec; 5():5629. PubMed ID: 25434740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterelogous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives.
    Zhao L; Teklemariam T; Hantash BM
    Stem Cell Res; 2014 Sep; 13(2):342-54. PubMed ID: 25218797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generating hESCs with reduced immunogenicity by disrupting TAP1 or TAPBP.
    Cui D; Wang J; Zeng Y; Rao L; Chen H; Li W; Li Y; Li H; Cui C; Xiao L
    Biosci Biotechnol Biochem; 2016 Aug; 80(8):1484-91. PubMed ID: 27068360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of alloimmune response by commensal gut microbiota and potential new avenues to influence the outcome of allogeneic transplantation by modification of the 'gut culture'.
    Kanangat S
    Int J Immunogenet; 2017 Feb; 44(1):1-6. PubMed ID: 28044415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histocompatible embryonic stem cells by parthenogenesis.
    Kim K; Lerou P; Yabuuchi A; Lengerke C; Ng K; West J; Kirby A; Daly MJ; Daley GQ
    Science; 2007 Jan; 315(5811):482-6. PubMed ID: 17170255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells.
    Dressel R; Nolte J; Elsner L; Novota P; Guan K; Streckfuss-Bömeke K; Hasenfuss G; Jaenisch R; Engel W
    FASEB J; 2010 Jul; 24(7):2164-77. PubMed ID: 20145206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity.
    Fairchild PJ; Horton C; Lahiri P; Shanmugarajah K; Davies TJ
    Regen Med; 2016 Dec; 11(8):817-829. PubMed ID: 27905261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune privilege for stem cells: not as simple as it looked.
    Chidgey AP; Boyd RL
    Cell Stem Cell; 2008 Oct; 3(4):357-8. PubMed ID: 18940724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advancements towards the derivation of immune-compatible patient-specific human embryonic stem cell lines.
    Drukker M
    Semin Immunol; 2008 Apr; 20(2):123-9. PubMed ID: 18160306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell medicine encounters the immune system.
    Bradley JA; Bolton EM; Pedersen RA
    Nat Rev Immunol; 2002 Nov; 2(11):859-71. PubMed ID: 12415309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells.
    Guha P; Morgan JW; Mostoslavsky G; Rodrigues NP; Boyd AS
    Cell Stem Cell; 2013 Apr; 12(4):407-12. PubMed ID: 23352605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for future histocompatible stem cell therapy.
    Nehlin JO; Barington T
    Biogerontology; 2009 Aug; 10(4):339-76. PubMed ID: 19219637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.
    Tang C; Weissman IL; Drukker M
    Methods Mol Biol; 2013; 1029():17-31. PubMed ID: 23756939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.